{7 (cladribine 10 MG Oral Tablet) } Pack — RxCUI 2122649
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Cladribine: what it is, how it’s used, side effects, and interactions.
- It's actually both, depending on the form. The oral tablets (brand name Mavenclad) are approved to treat relapsing forms of multiple sclerosis in adults — specifically for people w...
- What exactly is cladribine used for — is it a chemotherapy or an MS drug?
- Not exactly like a daily pill. The oral tablets are taken in a structured course — two yearly treatment courses, and each course is split into two short cycles of daily dosing. So...
- How do I actually take the MS tablets — do I take them every day?
🕸️ Concept Web — How {7 (cladribine 10 MG Oral Tablet) } Pack Connects
RxCUI 2122649 Generic pack · GPCK
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Cladribine
44157IN
-
Cladribine
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Mavenclad
2122636BN
-
Mavenclad
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Cladribine Oral Tablet
2122633SCDF -
Cladribine Oral Product
2122631SCDG -
Cladribine Pill
2122632SCDG -
Cladribine Oral Tablet [Mavenclad]
2122638SBDF -
Mavenclad Oral Product
2122639SBDG -
Mavenclad Pill
2122640SBDG -
Pack
746839DF -
Oral Product
1151131DFG - +1 more in this family
-
Cladribine Oral Tablet
-
Clinical & branded drugs 4
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Cladribine 10 MG Oral Tablet
2122634SCD -
Cladribine 10 MG
2122630SCDC -
Cladribine 10 MG Oral Tablet [Mavenclad]
2122641SBD -
Cladribine 10 MG [Mavenclad]
2122637SBDC
-
Cladribine 10 MG Oral Tablet
-
Packs 1
Fixed collections of drugs packaged and sold together, like dose packs.
🔀 Generic ⇄ Brand Crosswalk
Generic (Clinical) Concepts
-
Cladribine 10 MG Oral Tablet
SCD · 2122634 -
Cladribine 10 MG
SCDC · 2122630 -
Cladribine Oral Tablet
SCDF · 2122633 -
Cladribine Oral Product
SCDG · 2122631 -
Cladribine Pill
SCDG · 2122632
Brand-Name Concepts
-
Cladribine 10 MG Oral Tablet [Mavenclad]
SBD · 2122641 -
{7 (cladribine 10 MG Oral Tablet [Mavenclad]) } Pack [Mavenclad 7 Tablet Pack]
BPCK · 2122650 -
Cladribine 10 MG [Mavenclad]
SBDC · 2122637 -
Cladribine Oral Tablet [Mavenclad]
SBDF · 2122638 -
Mavenclad Oral Product
SBDG · 2122639 -
Mavenclad Pill
SBDG · 2122640 -
Mavenclad
BN · 2122636
📦 FDA Products & Package NDCs
4 products · 28 package NDCs
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 00781-8201-37 | 9 TABLET in 1 CARTON (0781-8201-37) | Cladribine | Sandoz Inc. | 2026-04-29 |
| 00781-8201-51 | 5 TABLET in 1 CARTON (0781-8201-51) | Cladribine | Sandoz Inc. | 2026-04-29 |
| 00781-8201-68 | 6 TABLET in 1 CARTON (0781-8201-68) | Cladribine | Sandoz Inc. | 2026-04-29 |
| 00781-8201-71 | 7 TABLET in 1 CARTON (0781-8201-71) | Cladribine | Sandoz Inc. | 2026-04-29 |
| 00781-8201-80 | 10 TABLET in 1 CARTON (0781-8201-80) | Cladribine | Sandoz Inc. | 2026-04-29 |
| 00781-8201-85 | 8 TABLET in 1 CARTON (0781-8201-85) | Cladribine | Sandoz Inc. | 2026-04-29 |
| 00781-8201-94 | 4 TABLET in 1 CARTON (0781-8201-94) | Cladribine | Sandoz Inc. | 2026-04-29 |
| 44087-4000-00 | 5 BLISTER PACK in 1 CARTON (44087-4000-0) / 2 TABLET in 1 B... | Mavenclad | EMD Serono, Inc. | 2019-04-01 |
| 44087-4000-04 | 4 BLISTER PACK in 1 CARTON (44087-4000-4) / 1 TABLET in 1 B... | Mavenclad | EMD Serono, Inc. | 2019-04-01 |
| 44087-4000-05 | 5 BLISTER PACK in 1 CARTON (44087-4000-5) / 1 TABLET in 1 B... | Mavenclad | EMD Serono, Inc. | 2019-04-01 |
| 44087-4000-06 | 6 BLISTER PACK in 1 CARTON (44087-4000-6) / 1 TABLET in 1 B... | Mavenclad | EMD Serono, Inc. | 2019-04-01 |
| 44087-4000-07 | 7 BLISTER PACK in 1 CARTON (44087-4000-7) / 1 TABLET in 1 B... | Mavenclad | EMD Serono, Inc. | 2019-04-01 |
| 44087-4000-08 | 8 BLISTER PACK in 1 CARTON (44087-4000-8) / 1 TABLET in 1 B... | Mavenclad | EMD Serono, Inc. | 2019-04-01 |
| 44087-4000-09 | 9 BLISTER PACK in 1 CARTON (44087-4000-9) / 1 TABLET in 1 B... | Mavenclad | EMD Serono, Inc. | 2019-04-01 |
| 60505-4791-01 | 10 TABLET in 1 CARTON (60505-4791-1) | Cladribine | Apotex Corp. | 2025-11-25 |
| 60505-4791-04 | 4 TABLET in 1 CARTON (60505-4791-4) | Cladribine | Apotex Corp. | 2025-11-25 |
| 60505-4791-05 | 5 TABLET in 1 CARTON (60505-4791-5) | Cladribine | Apotex Corp. | 2025-11-25 |
| 60505-4791-06 | 6 TABLET in 1 CARTON (60505-4791-6) | Cladribine | Apotex Corp. | 2025-11-25 |
| 60505-4791-07 | 7 TABLET in 1 CARTON (60505-4791-7) | Cladribine | Apotex Corp. | 2025-11-25 |
| 60505-4791-08 | 8 TABLET in 1 CARTON (60505-4791-8) | Cladribine | Apotex Corp. | 2025-11-25 |
| 60505-4791-09 | 9 TABLET in 1 CARTON (60505-4791-9) | Cladribine | Apotex Corp. | 2025-11-25 |
| 62049-0286-04 | 4 TABLET in 1 CARTON (62049-286-04) | Cladribine | Genvion Corporation | 2025-11-25 |
| 62049-0286-05 | 5 TABLET in 1 CARTON (62049-286-05) | Cladribine | Genvion Corporation | 2025-11-25 |
| 62049-0286-06 | 6 TABLET in 1 CARTON (62049-286-06) | Cladribine | Genvion Corporation | 2025-11-25 |
| 62049-0286-07 | 7 TABLET in 1 CARTON (62049-286-07) | Cladribine | Genvion Corporation | 2025-11-25 |
| 62049-0286-08 | 8 TABLET in 1 CARTON (62049-286-08) | Cladribine | Genvion Corporation | 2025-11-25 |
| 62049-0286-09 | 9 TABLET in 1 CARTON (62049-286-09) | Cladribine | Genvion Corporation | 2025-11-25 |
| 62049-0286-10 | 10 TABLET in 1 CARTON (62049-286-10) | Cladribine | Genvion Corporation | 2025-11-25 |
🗃️ Sources & Limits
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.